Prognostic value of temporal muscle thickness in pediatric medulloblastoma patients aged 3-12 years.

IF 3.1 2区医学 Q2 CLINICAL NEUROLOGY

Journal of Neuro-Oncology Pub Date : 2025-12-01 Epub Date: 2025-09-29 DOI:10.1007/s11060-025-05229-0

Xu An, Junhua Wang, Jingzhe Yuan, Xuan Zhou, Xiaozhu Liu, Xiaoyan Sun, Jian Gong, Qingnan Wu, Yunwei Ou

{"title":"Prognostic value of temporal muscle thickness in pediatric medulloblastoma patients aged 3-12 years.","authors":"Xu An, Junhua Wang, Jingzhe Yuan, Xuan Zhou, Xiaozhu Liu, Xiaoyan Sun, Jian Gong, Qingnan Wu, Yunwei Ou","doi":"10.1007/s11060-025-05229-0","DOIUrl":null,"url":null,"abstract":"Purpose: This retrospective, multicenter cohort study aimed to investigate the prognostic significance of temporal muscle thickness (TMT) in medulloblastoma (MB) patients.Methods: Preoperative cranial MRI was used to measure TMT. Patients were divided into training and test cohorts. An optimal TMT cutoff for progression-free survival (PFS) and overall survival (OS) was established.Results: Among the 303 enrolled MB patients, TMT was found to be associated with prognosis in the 230 patients aged 3-12 years. TMT demonstrated positive correlations with age and body mass index, while inverse associations were observed with the presence of hydrocephalus and metastasis. A TMT cutoff value of 6.115 mm was established in the training cohort, which served as a significant threshold for both PFS and OS. The 5-year PFS rates were (38.0 ± 11.5) % (low mean-TMT group) versus (88.3 ± 3.2) % (high mean-TMT group), and OS rates were (57.2 ± 8.7) % versus (96.5 ± 1.7) %, respectively. The multivariate Cox regression revealed significantly better PFS (hazard ratio (HR) = 0.165; 95% confidence interval (CI): 0.064-0.427; P < 0.001) and OS (HR = 0.064; 95% CI: 0.020-0.207; P < 0.001) in patients above versus below this cutoff. These findings were validated in test cohort and two independent validation cohorts.Conclusion: MRI-measured TMT is a potential prognostic indicator for MB patients aged 3-12 years, and may help guide risk stratification and treatment planning. To validate its clinical applicability, large-sample prospective researches remain essential.","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1235-1246"},"PeriodicalIF":3.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-025-05229-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This retrospective, multicenter cohort study aimed to investigate the prognostic significance of temporal muscle thickness (TMT) in medulloblastoma (MB) patients.

Methods: Preoperative cranial MRI was used to measure TMT. Patients were divided into training and test cohorts. An optimal TMT cutoff for progression-free survival (PFS) and overall survival (OS) was established.

Results: Among the 303 enrolled MB patients, TMT was found to be associated with prognosis in the 230 patients aged 3-12 years. TMT demonstrated positive correlations with age and body mass index, while inverse associations were observed with the presence of hydrocephalus and metastasis. A TMT cutoff value of 6.115 mm was established in the training cohort, which served as a significant threshold for both PFS and OS. The 5-year PFS rates were (38.0 ± 11.5) % (low mean-TMT group) versus (88.3 ± 3.2) % (high mean-TMT group), and OS rates were (57.2 ± 8.7) % versus (96.5 ± 1.7) %, respectively. The multivariate Cox regression revealed significantly better PFS (hazard ratio (HR) = 0.165; 95% confidence interval (CI): 0.064-0.427; P < 0.001) and OS (HR = 0.064; 95% CI: 0.020-0.207; P < 0.001) in patients above versus below this cutoff. These findings were validated in test cohort and two independent validation cohorts.

Conclusion: MRI-measured TMT is a potential prognostic indicator for MB patients aged 3-12 years, and may help guide risk stratification and treatment planning. To validate its clinical applicability, large-sample prospective researches remain essential.

查看原文本刊更多论文

颞肌厚度对3-12岁儿童成神经管细胞瘤患者的预后价值。

目的：本回顾性、多中心队列研究旨在探讨颞肌厚度（TMT）在髓母细胞瘤（MB）患者中的预后意义。方法：术前采用颅脑MRI检测TMT。患者被分为训练组和测试组。建立了无进展生存期（PFS）和总生存期（OS）的最佳TMT截止时间。结果：在303例入组的MB患者中，发现TMT与230例3-12岁患者的预后相关。TMT与年龄和体重指数呈正相关，而与脑积水和转移呈负相关。在训练队列中，TMT临界值为6.115 mm，这是PFS和OS的重要阈值。5年PFS分别为（38.0±11.5）%（低平均tmt组）和（88.3±3.2）%（高平均tmt组），OS分别为（57.2±8.7）%和（96.5±1.7）%。多因素Cox回归显示PFS明显改善(风险比(HR) = 0.165；95%置信区间（CI）： 0.064-0.427；结论：mri测量TMT是3-12岁MB患者的潜在预后指标，有助于指导风险分层和治疗计划。为了验证其临床适用性，大样本前瞻性研究仍然是必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuro-Oncology 医学-临床神经学

CiteScore

6.60

自引率

7.70%

发文量

277

审稿时长

3.3 months

期刊介绍： The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.